Fresenius Medical Care AG & Co. KGaA (ETR:FME) received a €82.00 ($95.35) price objective from stock analysts at Jefferies Financial Group in a research report issued to clients and investors on Tuesday. The brokerage presently has a “neutral” rating on the stock. Jefferies Financial Group’s target price suggests a potential downside of 5.96% from the company’s previous close.

A number of other research firms also recently issued reports on FME. JPMorgan Chase & Co. set a €97.90 ($113.84) target price on Fresenius Medical Care AG & Co. KGaA and gave the stock a “buy” rating in a research report on Wednesday, August 29th. Goldman Sachs Group set a €98.00 ($113.95) target price on Fresenius Medical Care AG & Co. KGaA and gave the stock a “buy” rating in a research report on Thursday, August 30th. HSBC set a €107.00 ($124.42) target price on Fresenius Medical Care AG & Co. KGaA and gave the stock a “buy” rating in a research report on Tuesday, August 28th. Barclays set a €87.20 ($101.40) target price on Fresenius Medical Care AG & Co. KGaA and gave the stock a “neutral” rating in a research report on Friday, August 31st. Finally, UBS Group set a €86.00 ($100.00) target price on Fresenius Medical Care AG & Co. KGaA and gave the stock a “neutral” rating in a research report on Friday, August 31st. Nine equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of €95.22 ($110.72).

Shares of FME stock opened at €87.00 ($101.16) on Tuesday. Fresenius Medical Care AG & Co. KGaA has a fifty-two week low of €75.53 ($87.83) and a fifty-two week high of €93.82 ($109.09).

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the U.S.

Featured Article: Stock Split

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (ETR:FME)

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.